Recent News

• 03.11.2025 - atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
• 03.05.2025 - atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression
• 02.24.2025 - atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
• 02.24.2025 - Mark Scott
• 02.20.2025 - atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
• 02.13.2025 - atai Life Sciences Announces Pricing of Public Offering of Common Shares
• 02.12.2025 - atai Life Sciences Announces Proposed Public Offering of Common Shares
• 01.28.2025 - atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
• 01.10.2025 - atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
• 12.03.2024 - ACG Announces Results of Annual General Meeting of Shareholders

Recent Filings

• 02.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.03.2024 - EX-99.1 EX-99.1
• 12.03.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 12.03.2024 - EX-99.1 EX-99.1
• 12.03.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]